J&J/Bavarian Nordic launching phase II Ebola vaccine trial

Healthy volunteers in England and France will be tested with the vaccine to assess safety, tolerabilty and immunogenicity. 

By Nicole Gray • July 16, 2015

Roche's PD-L1 drug slows bladder cancer growth in trials

Atezolizumab shrank tumors in patients with advanced or metastatic urothelial bladder cancer.

By Nicole Gray • July 13, 2015

Explore the Trendline➔

Neuroscience drug development

Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.

By BioPharma Dive staff

Study: Type 2 diabetes linked with cognitive decline

According to a new study, patients diagnosed with diabetes experience significant cognitive decline within a two-year period.

By Nicole Gray • July 13, 2015

A 21st century diabetes option: Will Oramed be first to market with oral insulin?

According to Oramed’s COO, Josh Hexter, oral insulin represents a first-in-class treatment option for diabetes and promises to be a truly disruptive force in a challenging therapeutic area.

By Nicole Gray • July 10, 2015

Another Indian CRO in hot water, this time with the WHO

According to the World Health Organization, Chennai-based Quest Life Sciences egregiously mishandled clinical trial results.

By Nicole Gray • July 8, 2015

J&J moves HIV vax to human trials after 50% protection rate in monkeys

Six out of 12 monkeys who received the vaccine were protected from HIV infection. 

By Nicole Gray • July 6, 2015

Another Roche Alzheimer's drug disappoints

Sembragiline did not demonstrate cognitive benefit in treated patients after 52 weeks. 

By Nicole Gray • July 6, 2015

Roche impresses with strong phase III data for MS drug candidate

But hefty competitors like Novartis and Biogen loom on the horizon.

By Nicole Gray • July 1, 2015

Celgene & Juno just struck a blockbuster $1B collab deal—but does it make sense?

Some industry observers are raising their eyebrows at the sheer amount of cash that Celgene is pumping into the deal. 

By Nicole Gray • June 30, 2015

With new Cosentyx data, Novartis slated to nab huge psoriasis market share

The therapy, approved in January for plaque psoriasis, has now also shown rapid and long-lasting efficacy for psoriatic arthritis. And the firm could rake in $4 billion to $5 billion in sales as a result.

By Sy Mukherjee • June 29, 2015

Lilly's data mining may pay off with nearly-abandoned Alzheimer's drug

In 2012, researchers at Eli Lilly were ready to give up on solanezumab, an experimental drug for Alzheimer's disease. But results from two studies changed their minds.

By Nicole Gray • June 29, 2015

Bristol-Myers calls it quits on any new virology R&D programs

But the company's ongoing programs in virology will remain in place. 

By Nicole Gray • June 26, 2015

Study: Combo Rx regimen can treat bipolar depression

Cyclurad, a combination of Ketamine, the mood stabilizer Lurasidone, and a tubreculosis drug, has long-term efficacy in hard-to-treat bipolar depression, according to a study.

By Nicole Gray • June 25, 2015

Alcobra flops as placebo beats its drug in phase II

In clinical trials, MDX was tested for treatment of both ADHD and fragile X syndrome and failed to meet primary endpoints.

By Nicole Gray • June 25, 2015

The early winners and losers in ASCO's highly anticipated cancer drug scorecard

ASCO's drug scorecard is designed to simplify therapeutic decision-making by comparing survival data for different regimens with costs and side effects. 

By Nicole Gray • June 24, 2015

Lilly, Teva to present late-stage migraine drug data

Both companies are developing antibody-based migraine treatments based on the same target—calcitonin gene-related peptide (CGRP).

By Nicole Gray • June 22, 2015

Tekmira's Ebola trials halted over efficacy concerns

TKM-Ebola-Guinea did not demonstrate therapeutic efficacy in clinical trials.

By Nicole Gray • June 22, 2015

Amgen's colorectal cancer drug shines in phase III

Vectibix is looking like a winner.

By Nicole Gray • June 19, 2015

BioMarin's childhood dwarfism drug nails it in phase II

The progress from preclinical studies to promising phase II progress has been stunningly fast.

By Nicole Gray • June 19, 2015

Your BIO2015 guide: Biotech in space, a BIO name change and more

There were fascinating discussions and insights abound at the massive annual meeting. And when we say "biotech in space," we mean the "outside-of-this-planet" kind.

By Sy Mukherjee • June 18, 2015

Ebola vaccines require greater speed in trials

Successful containment efforts in Africa have an unavoidable consequence.

By Nicole Gray • June 18, 2015

Synergy Pharma shares soar from constipation drug study

Positive results on the efficacy of Plecanatide, Synergy's lead drug, pushed the stock up 66% yesterday.

By Nicole Gray • June 18, 2015

Avalanche gene therapy safe, modestly effective in AMD patients

The biotech also has a potential deal in place with Regeneron. 

By Nicole Gray • June 16, 2015

The curious case of Lilly's share price and its Alzheimer's hopeful data

There is a great deal of excitment surrounding the company's investigational Alzheimer's drug, solanezumab.

By Nicole Gray • June 15, 2015

1st sickle cell patient treated with Bluebird's pioneering gene therapy doing well

A 13-year-old French boy with sickle cell anemia is the first patient to be treated with Bluebird Bio's Lentiglobin BB305. 

By Nicole Gray • June 15, 2015